

Rana R Mckay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2673227/publications.pdf>

Version: 2024-02-01

121
papers

4,630
citations

159585

30
h-index

114465

63
g-index

124
all docs

124
docs citations

124
times ranked

9340
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
2	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, S-1-S-50.	4.9	245
3	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.	1.9	207
4	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	1.6	174
5	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	10.7	124
6	Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2471-2479.	7.0	109
7	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	1.6	109
8	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	3.4	89
9	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
10	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248.	1.6	69
11	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736.	1.6	69
12	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3615-3623.	1.6	65
13	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , 2015, 121, 3435-3443.	4.1	64
14	Depth of Remission is a Prognostic Factor for Survival in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015, 67, 952-958.	1.9	61
15	Mental health outcomes in elderly men with prostate cancer1Equal contribution.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1333-1340.	1.6	59
16	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 372-381.	5.4	59
17	Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1374-1380.	2.5	57
18	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018, 6, 402-408.	3.4	56

#	ARTICLE	IF	CITATIONS
19	<i>CDK12</i> -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	3.0	51
20	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021, 127, 840-849.	4.1	51
21	Neoadjuvant therapy for localized and locally advanced renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 31-37.	1.6	49
22	Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 364-372.	3.9	48
23	Association of Treatment With 5 α -Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. <i>JAMA Internal Medicine</i> , 2019, 179, 812.	5.1	44
24	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021, 13, 155.	8.2	44
25	Adrenocortical carcinoma: The management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 123-132.	4.4	43
26	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	1.9	42
27	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e289-e298.	1.9	40
28	Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. <i>Drugs</i> , 2013, 73, 1417-1430.	10.9	39
29	Statins and survival outcomes in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2016, 52, 155-162.	2.8	39
30	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2926-2937.	1.6	36
31	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	2.9	35
32	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 724-732.	1.9	34
33	Comprehensive Analysis of Survival Outcomes in Non-“Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 652-660.e1.	1.9	32
34	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 532-542.	1.0	31
35	Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration. <i>Cancer</i> , 2021, 127, 403-411.	4.1	29
36	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	29

#	ARTICLE	IF	CITATIONS
37	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021, 81, 433-439.	2.3	29
38	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016, 122, 411-419.	4.1	27
39	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). <i>Lancet Oncology</i> , 2022, 23, 899-909.	10.7	26
40	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 17.e9-17.e18.	1.6	24
41	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , 2018, 24, 4081-4088.	7.0	24
42	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
43	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	6.4	24
44	Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e505-e512.	1.9	24
45	Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. <i>Cancer</i> , 2022, 128, 770-777.	4.1	23
46	Disparities in germline testing among racial minorities with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 403-410.	3.9	22
47	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	1.0	21
48	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer Clinical Trials: Potential Roles and Possible Pitfalls. <i>Translational Oncology</i> , 2014, 7, 120-129.	3.7	20
49	Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. <i>Cancer</i> , 2019, 125, 1070-1080.	4.1	20
50	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 221-229.	1.9	18
51	Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1188-1193.	0.8	18
52	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
53	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	4.1	16
54	Cardiovascular toxicities associated with abiraterone compared to enzalutamide: A pharmacovigilance study. <i>EClinicalMedicine</i> , 2021, 36, 100887.	7.1	16

#	ARTICLE	IF	CITATIONS
55	Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy. <i>Cancer</i> , 2018, 124, 2939-2947.	4.1	15
56	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 388-396.	3.9	15
57	Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2021, 80, 295-303.	1.9	15
58	Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. <i>Molecular Oncology</i> , 2021, 15, 2330-2344.	4.6	14
59	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-11.	3.0	13
60	Rising Serum Uric Acid Level Is Negatively Associated with Survival in Renal Cell Carcinoma. <i>Cancers</i> , 2019, 11, 536.	3.7	13
61	Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2019, 79, 244-258.	2.3	13
62	Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans. <i>European Urology Open Science</i> , 2021, 30, 1-10.	0.4	13
63	The Role of miRNAs in Prostate Cancer. <i>European Urology</i> , 2015, 68, 589-590.	1.9	12
64	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 463-471.	1.9	12
65	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e327-e333.	1.9	12
66	Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. <i>JCO Global Oncology</i> , 2021, 7, 495-505.	1.8	12
67	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	1.6	12
68	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e299-e305.	1.9	11
69	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e598-e609.	1.9	11
70	Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 210-219.	3.9	11
71	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 187-197.	3.8	11
72	Association of Health-Care System With Prostate Cancer-Specific Mortality in African American and Non-Hispanic White Men. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1343-1351.	6.3	11

#	ARTICLE	IF	CITATIONS
73	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26.		10
74	Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer. European Urology Oncology, 2019, 2, 584-588.	5.4	10
75	Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer, 2015, 121, 2603-2611.	4.1	9
76	Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology, 2019, 76, 852-860.	1.9	9
77	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. Advances in Therapy, 2020, 37, 4910-4929.	2.9	9
78	Immunotherapy for Localized Prostate Cancer. Urologic Clinics of North America, 2020, 47, 443-456.	1.8	9
79	Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. Advances in Therapy, 2022, 39, 2515-2532.	2.9	9
80	An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 199.e15-199.e21.	1.6	9
81	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer, 2019, 125, 524-532.	4.1	8
82	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. Oncologist, 2021, 26, e905-e906.	3.7	8
83	Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer, 2022, 20, 326-333.	1.9	8
84	Diagnosis of Renal Cell Carcinoma. Surgical Pathology Clinics, 2015, 8, 657-662.	1.7	7
85	Substrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1068-1076.	0.8	6
86	Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer and Prostatic Diseases, 2020, 23, 689-695.	3.9	6
87	Analysis of <i>CDK12</i> alterations in a pan-cancer database. Cancer Medicine, 2022, 11, 753-763.	2.8	6
88	Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer. Hematology/Oncology Clinics of North America, 2013, 27, 1261-1283.	2.2	5
89	Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. Journal of Global Oncology, 2018, 4, 1-14.	0.5	5
90	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	1.9	5

#	ARTICLE	IF	CITATIONS
91	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100448.	3.0	5
92	The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 443-450.e1.	1.9	4
93	Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. <i>European Urology Focus</i> , 2020, 6, 17-25.	3.1	4
94	Prognostic Significance of Pancreatic Metastases in Patients With Advanced Renal Cell Carcinoma Treated With Systemic Therapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e367-e373.	1.9	4
95	Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 564.e1-564.e10.	1.9	4
96	SMART COVID Navigator, a Clinical Decision Support Tool for COVID-19 Treatment: Design and Development Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e29279.	4.3	4
97	The renal clear cell carcinoma immune landscape. <i>Neoplasia</i> , 2022, 24, 145-154.	5.3	4
98	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	4
99	Germline alterations among Hispanic men with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 561-567.	3.9	4
100	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
101	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e350-e359.	1.9	3
102	Association of prior local therapy and outcomes with programmed cell death ligand-1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	2.5	3
103	Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, S385-S385.	1.7	2
104	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4559-4559.	1.6	2
105	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. <i>Journal of Clinical Oncology</i> , 2015, 33, 405-405.	1.6	2
106	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 408-408.	1.6	2
107	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. <i>Journal of Medical Internet Research</i> , 2019, 21, e12044.	4.3	2
108	Asymptomatic detection of SARS-CoV-2 among cancer patients receiving infusional anti-cancer therapy. <i>Cancer Medicine</i> , 2021, 10, 8763.	2.8	2

#	ARTICLE	IF	CITATIONS
109	Impact of age on treatment response in men with prostate cancer treated with radiotherapy. BJUI Compass, 2022, 3, 243-250.	1.3	2
110	Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer. Journal of the National Cancer Institute, 2022, 114, 600-608.	6.3	2
111	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. Clinical Genitourinary Cancer, 2018, 16, 13-20.e3.	1.9	1
112	Management of bone complications in patients with genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 94-104.	1.6	1
113	Germline alterations among Hispanic men with prostate cancer.. Journal of Clinical Oncology, 2021, 39, 10534-10534.	1.6	1
114	Overall survival (OS) among Medicare beneficiaries receiving sipuleucel-T (sip-T) versus oral treatment for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 42-42.	1.6	1
115	Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 681-681.	1.6	1
116	Prostate cancer 2012: where do we stand and where are we heading?. Oncology, 2012, 26, 1222, 1224.	0.5	1
117	Clinical implications of genetic aberrations in metastatic prostate cancer. Current Opinion in Urology, 2019, 29, 319-325.	1.8	0
118	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2021, 39, 354-354.	1.6	0
119	Treatment Discontinuation in Patients with Muscle-Invasive Bladder Cancer Undergoing Chemoradiation. Advances in Radiation Oncology, 2021, 7, 100836.	1.2	0
120	Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 435-435.	1.6	0
121	Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0